BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25246112)

  • 21. Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.
    Anderson RA; Cameron D; Clatot F; Demeestere I; Lambertini M; Nelson SM; Peccatori F
    Hum Reprod Update; 2022 May; 28(3):417-434. PubMed ID: 35199161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Clinical Value and Interpretation of Anti-Müllerian Hormone in Women With Cancer.
    Anderson RA; Su HI
    Front Endocrinol (Lausanne); 2020; 11():574263. PubMed ID: 33117288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
    Oktay KH; Bedoschi G; Goldfarb SB; Taylan E; Titus S; Palomaki GE; Cigler T; Robson M; Dickler MN
    Fertil Steril; 2020 Jun; 113(6):1251-1260.e1. PubMed ID: 32331767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Lee DY; Park YH; Lee JE; Choi D
    Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review.
    Iwase A; Nakamura T; Nakahara T; Goto M; Kikkawa F
    Reprod Sci; 2015 May; 22(5):519-26. PubMed ID: 25228631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-treatment anti-Mullerian hormone (AMH) levels predict long-term ovarian dysfunction in women with hematological malignancies.
    Kongkiatkamon S; Chintabanyat A; Polprasert C; Uaprasert N; Rojnuckarin P
    Hematology; 2022 Dec; 27(1):181-186. PubMed ID: 35068389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of long-term using of hormonal contraception on anti-Müllerian hormone secretion.
    Kucera R; Ulcova-Gallova Z; Topolcan O
    Gynecol Endocrinol; 2016; 32(5):383-5. PubMed ID: 26651155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling Variation in the Reproductive Lifespan of Female Adolescent and Young Adult Cancer Survivors Using AMH.
    Su HI; Kwan B; Whitcomb BW; Shliakhsitsava K; Dietz AC; Stark SS; Martinez E; Sluss PM; Sammel MD; Natarajan L
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2740-51. PubMed ID: 32270202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
    Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
    Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy.
    Dillon KE; Sammel MD; Prewitt M; Ginsberg JP; Walker D; Mersereau JE; Gosiengfiao Y; Gracia CR
    Fertil Steril; 2013 Feb; 99(2):477-83. PubMed ID: 23084267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of postchemotherapy ovarian function using markers of ovarian reserve.
    Henry NL; Xia R; Schott AF; McConnell D; Banerjee M; Hayes DF
    Oncologist; 2014 Jan; 19(1):68-74. PubMed ID: 24319018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-Müllerian hormone as a marker of ovarian reserve following chemotherapy in patients with gestational trophoblastic neoplasia.
    Iwase A; Sugita A; Hirokawa W; Goto M; Yamamoto E; Takikawa S; Nakahara T; Nakamura T; Kondo M; Kikkawa F
    Eur J Obstet Gynecol Reprod Biol; 2013 Apr; 167(2):194-8. PubMed ID: 23274042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103.
    Ruddy KJ; O'Neill A; Miller KD; Schneider BP; Baker E; Sparano JA; Dang C; Northfelt DW; Sledge GW; Partridge AH
    Breast Cancer Res Treat; 2014 Apr; 144(3):591-7. PubMed ID: 24584876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of the Ultrasensitive Anti-Müllerian Hormone Assay for Predicting True Ovarian Reserve.
    Iwase A; Osuka S; Nakamura T; Kato N; Takikawa S; Goto M; Kikkawa F
    Reprod Sci; 2016 Jun; 23(6):756-60. PubMed ID: 26614267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan.
    Birch Petersen K; Hvidman HW; Forman JL; Pinborg A; Larsen EC; Macklon KT; Sylvest R; Andersen AN
    Hum Reprod; 2015 Oct; 30(10):2364-75. PubMed ID: 26311148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infertile women below the age of 40 have similar anti-Müllerian hormone levels and antral follicle count compared with women of the same age with no history of infertility.
    Hvidman HW; Bentzen JG; Thuesen LL; Lauritsen MP; Forman JL; Loft A; Pinborg A; Nyboe Andersen A
    Hum Reprod; 2016 May; 31(5):1034-45. PubMed ID: 26965431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study.
    Brougham MF; Crofton PM; Johnson EJ; Evans N; Anderson RA; Wallace WH
    J Clin Endocrinol Metab; 2012 Jun; 97(6):2059-67. PubMed ID: 22472563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal follow-up in female Childhood Cancer Survivors: no signs of accelerated ovarian function loss.
    van der Kooi AL; van den Heuvel-Eibrink MM; van Noortwijk A; Neggers SJ; Pluijm SM; van Dulmen-den Broeder E; van Dorp W; Laven JS
    Hum Reprod; 2017 Jan; 32(1):193-200. PubMed ID: 27821706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors.
    Zhou B; Kwan B; Desai MJ; Nalawade V; Ruddy KJ; Nathan PC; Henk HJ; Murphy JD; Whitcomb BW; Su HI
    Fertil Steril; 2022 May; 117(5):1047-1056. PubMed ID: 35216831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.